NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Life Technologies and Affymetrix while it upgraded Myriad Genetics and Qiagen.

In a research note, analyst Isaac Ro made revisions to several life science tools and genomics-related firms to favor those "with high exposure to the US and strong [free cash flow] where capital allocation can improve." Changes were made also to reflect rising pressure in the European Union, continuing headwinds to the National Institutes of Health, and slower growth in China.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.